teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 45 Projects Releases Packages Wiki Activity Actions 1

auto-fix: strip 2 broken wiki links

Browse source 
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
This commit is contained in:
Teleo Agents 2026-03-19 16:06:59 +00:00
parent b5626d0095
commit 419edc4337
2 changed files with 2 additions and 2 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

2
domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md
View file

@ -115,7 +115,7 @@ International generic competition beginning January 2026 (Canada patent expiry,
### Additional Evidence (challenge)
*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19*
*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach | Added: 2026-03-19*
If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone), and if behavioral change persists after medication discontinuation, then the chronic use model may not be necessary for long-term value capture. This challenges the inflationary cost projection if the optimal intervention is time-limited medication + permanent behavioral change rather than lifetime pharmacotherapy.

2
domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md
View file

@ -97,7 +97,7 @@ GLP-1 behavioral adherence failures demonstrate that even breakthrough pharmacol
### Additional Evidence (extend)
*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19*
*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach | Added: 2026-03-19*
Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than placebo (7.6 kg) after discontinuation, while combination with exercise reduces regain to 3.5 kg. This suggests the low persistence rates may be economically rational from a patient perspective if medication alone provides no durable benefit—patients who discontinue without establishing exercise habits return to baseline regardless of medication duration.